The American is committed to investing 1 billion euros to bring out European nuggets in health.
It’s a great catch for Sofinnova. The European venture capital champion specializing in the life sciences seals a partnership with Apollo, the American private equity giant (513 billion dollars in assets under management, 31 billion dollars in market capitalization). Apollo will thus enter the capital of Sofinnova as a minority shareholder and contribute up to 1 billion euros to the raising of its funds. “This strategic partnership will enable us to accelerate Sofinnova’s growth and support the next generation of game-changing healthcare start-ups, rejoices Antoine Papiernik, president of Sofinnova Partners. In a context where innovation goes faster and costs more, it is necessary to be able to raise more and more funds in order to finance companies throughout their life cycle and help them bring new drugs to market. and therapeutic solutions.»
Read alsoSofinnova strengthens its leading position in Europe
Sofinnova, which is celebrating its 50th anniversary this year…